1. GPCR/G Protein
    Immunology/Inflammation
  2. CCR

CCR

CCR (Chemokine receptors) are cytokine receptors found on the surface of certain cells that interact with a type of cytokine called achemokine. There have been 19 distinct chemokine receptors described in mammals. Each has a 7-transmembrane (7TM) structure and couples to G-protein for signal transduction within a cell, making them members of a large protein family of G protein-coupled receptors. Following interaction with their specific chemokine ligands, chemokine receptors trigger a flux in intracellular calcium (Ca2+) ions (calcium signaling). This causes cell responses, including the onset of a process known as chemotaxis that traffics the cell to a desired location within the organism. Chemokine receptors are divided into different families, CXC chemokine receptors, CC chemokine receptors, CX3C chemokine receptors and XC chemokine receptors that correspond to the 4 distinct subfamilies of chemokines they bind. Specific chemokine receptors provide the portals for HIV to get into cells, and others contribute to inflammatory diseases and cancer.

CCR Related Products (22):

Cat. No. Product Name Effect Purity
  • HY-13004
    Maraviroc Antagonist 99.34%
    Maraviroc is a selective CCR5 antagonist, inhibits MIP-1α (IC50, 3.3 nM), MIP-1β (IC50, 7.2 nM), and RANTES (IC50, 5.2 nM) binding to cell membrane preparations of CCR5-expressing HEK-293.
  • HY-50674
    INCB3344 Antagonist 99.76%
    INCB3344 is a potent CCR2 antagonist with IC50 values of 5.1 nM (hCCR2) and 9.5 nM (mCCR2) in binding antagonism and 3.8 nM (hCCR2) and 7.8 nM (mCCR2) in antagonism of chemotaxis activity.
  • HY-13245
    PF-4136309 Antagonist 99.59%
    PF-4136309 is a potent, selective, and orally bioavailable CCR2 antagonist, with IC50 of 5.2 nM, 17 nM and 13 nM for human, mouse and rat CCR2.
  • HY-15724
    Vercirnon Antagonist 98.04%
    Vercirnon is a highly potent antagonist of CCR9, which has been implicated in the aetiology of inflammatory bowel diseases such as Crohn's disease.
  • HY-15418
    RS 504393 Antagonist 98.58%
    RS 504393 is a selective CCR2 chemokine receptor antagonist (IC50 values are 98 nM and > 100 μM for inhibition of human recombinant CCR2b and CCR1 receptors respectively).
  • HY-14882
    Cenicriviroc Antagonist
    Cenicriviroc is an orally active, dual CCR2/CCR5 antagonist, and displays potent anti-inflammatory and aninfective activity.
  • HY-108323
    Teijin compound 1 Antagonist
    Teijin compound 1 is a specific CCR 2 antagonist with IC50s of 24 and 180 nM in chemotaxis and binding assay, respectively.
  • HY-101038A
    ZK756326(dihydrochloride) Agonist 99.53%
    ZK756326 dihydrochloride is a nonpeptide chemokine receptor agonist for the CC chemokine receptor CCR8.
  • HY-12080
    BX471 Antagonist
    BX471 is a potent, selective non-peptide CCR1 antagonist with Ki of 1 nM for human CCR1, and exhibits 250-fold selectivity for CCR1 over CCR2, CCR5 and CXCR4.
  • HY-15450A
    INCB 3284 Antagonist 99.30%
    INCB 3284 is a potent, selective and orally bioavailable hCCR2 antagonist with IC50 of 3.7 nM(inhibition of monocyte chemoattractant protein-1 binding to hCCR2).
  • HY-13406
    TAK-779 Antagonist 99.72%
    TAK-779 is a highly potent and selective nonpeptide CCR5 antagonist with a IC50 value of 1.4 nM in the binding assay, TAK-779 also inhibited the replication of macrophage (M)-tropic HIV-1 (Ba-L strain) in both MAGI-CCR5 cells and PBMCs with EC50 values of
  • HY-50669
    MK-0812 Antagonist
    MK-0812 is a potent and selective CCR2 antagonist with low nM affinity for CCR2 on human monocytes.
  • HY-17377
    Vicriviroc maleate Antagonist
    Vicriviroc maleate(Sch-417690) is a CCR5 antagonist with IC50 of 0.91 nM in clinical development for the treatment of HIV-1.
  • HY-18611
    RS102895 hydrochloride Antagonist 98.98%
    RS102895 Hcl is a potent and specific CCR2 antagonist with binding IC50 of 360 nM, no significant inhibition on CCR1(IC50 > 17 uM).
  • HY-50669A
    MK-0812 Succinate Antagonist 99.57%
    MK-0812 Succinate is a potent and selective CCR2 antagonist with low nM affinity for CCR2 on human monocytes.
  • HY-15450
    INCB 3284 dimesylate Antagonist
    INCB 3284 is a potent, selective and orally bioavailable hCCR2 antagonist with IC50 of 3.7 nM.
  • HY-19974
    TAK-220 Antagonist
    TAK-220 is an orally bioavailable small-molecule CCR5 antagonist.
  • HY-100033
    NSC5844 Agonist >98.0%
    NSC5844 (RE640) is a bisquinoline compound with C-C chemokine receptor type 1 (CCR1)-agonistic properties.
  • HY-12080A
    BX471 hydrochloride Antagonist
    BX471 Hcl is a potent, selective non-peptide CCR1 antagonist (Ki = 1 nM for human CCR1); exhibits 250-fold selectivity for CCR1 over CCR2, CCR5 and CXCR4.
  • HY-U00064
    AZD2098 Inhibitor
    AZD2098 is a potent CC-chemokine receptor 4 (CCR4) inhibitor, used for asthma research.